Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. Read more about Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma.
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. Read more about CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. Read more about Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Read more about Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Read more about Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.
Vaccinating against cancer: getting to prime time. Read more about Vaccinating against cancer: getting to prime time.
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Read more about Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al. Read more about Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al.
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. Read more about Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
SP140 inhibits STAT1 signaling, induces IFN-? in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response. Read more about SP140 inhibits STAT1 signaling, induces IFN-? in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response.
